Oncology (Williston Park). 2020 Jul 15;34(7):252.
Results from the phase 3 HERO trial(NCT03085095), presented during the 2020 American Society of Clinical Oncology Virtual Scientific Program, indicated that relugolix (Relumina) demonstrated superiority over leuprolide (Lupron) in sustained testosterone suppression through 48 weeks, fast testosterone recovery after discontinuation, and a 50% reduction in major adverse cardiovascular events (MACE) in patients with advanced prostate cancer.
HERO 试验（NCT03085095）的 3 期结果，在美国临床肿瘤学会虚拟科学项目期间公布，表明与亮丙瑞林（Lupron）相比，瑞卢戈利（Relumina）在 48 周时持续抑制睾酮、停药后睾酮快速恢复以及晚期前列腺癌患者的主要不良心血管事件（MACE）减少 50%方面具有优越性。
